This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tuesday's Health Winners & Losers

Myriad Genetics (MYGN - Get Report) was trading higher after the company reported a fiscal second-quarter loss that beat analysts' expectations. After touching a 52-week high of $37.35, the stock was recently up $1.28, or 3.7%, to $36.33.

Shares of MedImmune (MEDI) were rising 1.7% even after Thomas Weisel Partners downgraded the stock to market-weight from overweight, citing a lack of new drugs in the pipeline. MedImmune, which is set to report fourth-quarter earnings on Wednesday, was recently up 58 cents to $34.22.

Among losers, Mentor (MNT), a Santa Barbara, Calif.-based maker of breast implants, posted fiscal third-quarter earnings that beat the Thomson First Call consensus, but its shares were still falling. Mentor was down $2.36, or 4.5%, to $50.32.

Elsewhere, Xoma Ltd. (XOMA - Get Report) was gaining 10.1% at $3.06, Martek Biosciences (MATK) was climbing 5.6% to $24.31, and Elan (ELN) was higher by 1.2% at $13.37.

Meanwhile, Nektar Therapeutics (NKTR) was slumping 3.7% to $11.73, Biogen Idec (BIIB - Get Report) shed 1.1% to $48.49, and Dow component Johnson & Johnson (JNJ - Get Report) was off 0.5% at $65.94.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIIB $264.50 0.52%
JNJ $112.56 0.30%
MYGN $34.09 0.44%
XOMA $0.75 -2.60%
ELN $0.00 0.00%


Chart of I:DJI
DOW 17,649.58 -1.68 -0.01%
S&P 500 2,049.63 -1.49 -0.07%
NASDAQ 4,719.8330 -5.8060 -0.12%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs